Novavax said it is pivoting toward a partnership-led model, including a licensing deal with Pfizer for its Matrix-M technology.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver?
Novavax said it is pivoting toward a partnership-led model, including a licensing deal with Pfizer for its Matrix-M technology.